Table 1 General characteristics patients classified according to vaccination status
Variables | Total cohort (n = 160) | Partially vaccinated (n = 69) | Fully vaccinated (n = 91) | p-value |
|---|---|---|---|---|
Demographics and comorbidities | ||||
Age, years | 71 (61.8–78) | 74 (66–79) | 69 (60–77.5) | .029* |
Gender (male) | 111 (69.38%) | 44 (63.77%) | 67 (73.63%) | 0.226 |
The presence of at least one comorbidity | 136 (85.00%) | 54 (78.26%) | 82 (90.11%) | .045* |
BMI ≥ 30 kg/m2 | 24 (15.00%) | 11 (15.94%) | 13 (14.29%) | 0.825 |
CHD | 53 (33.13%) | 19 (27.54%) | 34 (37.36%) | 0.236 |
COPD | 40 (25.00%) | 24 (34.78%) | 16 (17.58%) | .016* |
Diabetes | 47 (29.38%) | 24 (34.78%) | 23 (25.27%) | 0.222 |
CKD | 47 (29.38%) | 14 (20.29%) | 33 (36.26%) | .035* |
Immunosuppression | 48 (30.00%) | 12 (14.39%) | 36 (39.56%) | .003* |
Clinical ICU presenteng features | ||||
Pre-ICU hospital LOS, days | 3 (1–8) | 3 (1–5) | 4 (1–12) | .04* |
PaO2/FiO2 | 109 (83–146.5) | 100 (81.5–144) | 114 (83.5–152) | 0.364 |
Ongoing IMV | 50 (31.25%) | 20 (28.99%) | 30 (32.97%) | 0.610 |
Septic shock | 44 (27.50%) | 20 (28.99%) | 24 (26.37%) | 0.724 |
AKI III requiring CRRT | 26 (16.25%) | 8 (11.60%) | 18 (19.78%) | 0.198 |
Barotrauma | 16 (10.00%) | 6 (8.70%) | 10 (10.99%) | 0.792 |
Pulmonary embolism | 12 (7.50%) | 4 (5.80%) | 8 (8.79%) | 0.556 |
Concomitant infection | 58 (36.25%) | 22 (31.88%) | 36 (39.56%) | 0.407 |
Treatments at ICU admission | ||||
Dexamethasone | 135 (84.38%) | 66 (95.65%) | 69 (75.82%) | < .0001* |
Remdesivir | 71 (44.38%) | 36 (52.17%) | 35 (38.46%) | 0.108 |
IL-6 inhibitors | 31 (19.38%) | 14 (20.29%) | 17 (18.68%) | 0.842 |
Insulin | 61 (38.13%) | 23 (33.33%) | 38 (41.76%) | 0.325 |
Antibiotics | 102 (63.75%) | 38 (55.07%) | 64 (70.33%) | .067 |